替格瑞洛联合替罗非班对急性非ST段抬高心肌梗死患者血小板聚集率及预后的影响

发布时间：2018-09-12 08:00

【摘要】：目的探讨替格瑞洛联合替罗非班对急性非ST段抬高心肌梗死(NSTEMI)患者血小板聚集率及主要心血管不良事件的影响。方法明确诊断为NSTEMI并且在入院时采取早期保守策略的65例患者随机分为常规治疗组(对照组)30例和替格瑞洛+替罗非班组(研究组)35例。对比两组用药前及用药后24 h血小板聚集率的变化和30 d内主要心血管不良事件(MACE),同时评价抗血小板治疗的安全性。结果用药24 h后研究组血小板聚集率与对照组比较明显下降(P0.05)。与对照组比较,研究组30 d内MACE明显降低(P0.05);4 w时行超声心动图检查,研究组左室舒张末期内径(LVEDd)明显小于对照组(P0.05),研究组左心室射血分数(LVEF)明显大于对照组(P0.05)。研究组和对照组出血发生率无显著差别(P0.05)。结论替格瑞洛联合替罗非班对急性期非介入NSTEMI患者具有更强的抑制血小板聚集的作用,明显降低30 d内MACE事件,保护左心功能,且不增加出血风险。
[Abstract]:Objective to investigate the effects of tigrilol combined with tirofiban on platelet aggregation and major adverse cardiovascular events in patients with acute non-ST elevation myocardial infarction (NSTEMI). Methods Sixty-five patients with NSTEMI were randomly divided into conventional treatment group (control group) and tiglitrofiban group (study group). The changes of platelet aggregation rate before and after treatment were compared between the two groups, and the safety of anti-platelet therapy was evaluated by (MACE), the main cardiovascular adverse events within 30 days. Results the platelet aggregation rate in the study group was significantly lower than that in the control group after 24 hours (P0.05). Compared with the control group, the MACE in the study group decreased significantly (P0.05) at 4 weeks, the left ventricular end-diastolic diameter (LVEDd) in the study group was significantly lower than that in the control group (P0.05), and the left ventricular ejection fraction (LVEF) in the study group was significantly higher than that in the control group (P0.05). There was no significant difference in the incidence of hemorrhage between the study group and the control group (P0.05). Conclusion tigrilol combined with tirofiban has a stronger inhibitory effect on platelet aggregation in patients with acute non-interventional NSTEMI, significantly reduces MACE events within 30 days, protects left ventricular function, and does not increase the risk of bleeding.
【作者单位】：佳木斯市中心医院心内科;黑龙江省饶河县人民医院内科;佳木斯大学基础医学院;
【分类号】：R542.22

【参考文献】